Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
NCT02780310Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2016
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in adenoid cystic carcinoma (ACC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response Rate at 8 weeks. Started May 2016; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT02780310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780310.